News

Zacks.com on MSN5d
RXRX Doses First Patient in Early-Stage B-Cell Lymphomas Study
Recursion Pharmaceuticals doses the first patient in a phase I study of its investigational candidate, REC-3565, for treating B-cell lymphomas.
European Medical Journal4h
EBMT 2025 Interview: Magdalena Corona de Lapuerta
In this interview, Magdalena Corona de Lapuerta, recipient of the Jian-Jian Luan Award for Lymphoma Transplant Research, ...
The Globe and Mail20d
Non-Hodgkin’s Lymphoma Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies
DelveInsight’s, “Non-Hodgkin Lymphoma Pipeline Insight ... address adaptive immune resistance mechanisms to enhance anticancer activity against B-cell malignancies. The drug is being evaluated ...
Targeted Oncology12d
Disease Site and Access Factor into Selection of GVHD Therapy
During a live event, Catherine J. Lee, MD, MS, discussed the mechanism of action of approved therapies for chronic ...
The American Journal of Managed Care3d
Newly Approved Triplet Regimen Boosts Survival in R/R LBCL: Craig Portell, MD
ECHELON-3 (NCT04404283) principal investigator Craig A. Portell, MD, speaks to the significance of this triplet approval from ...
Rolling Out6d
5 astonishing advances in lymphoma treatment success
Discover how innovative lymphoma treatments are transforming patient outcomes, from targeted therapies to immunotherapy ...